13816results about How to "Quick release" patented technology

A method of communicating with a physiological sensor is disclosed. In an embodiment, the method includes supplying power through a first conductor in a first mode to the physiological sensor and communicating with an information element through the first conductor in a second mode. The physiological sensor includes the information element, a power supply configured to receive and store power from the first conductor in the first mode, and sensing circuitry configured to receive power from the first conductor in the first mode. The power supply releases the stored power to the sensing circuitry in the second mode.

A method for delivering a therapeutic agent to a predetermined location in a host is disclosed, wherein a liposome-encapsulated therapeutic agent is administered to the host, and an electrical field which encompasses a predetermined region within the host is established, such that as the liposome-encapsulated agent is exposed to the electrical field the release of the agent from the liposome to the predetermined region is enhanced.

An oral pharmaceutical modified release multiple-units composition for the administration of a therapeutically and/or prophylactically effective amount of a non-steroid anti-inflammatory drug substance to obtain both a relatively fast onset of the therapeutic effect and the maintenance of a therapeutically active plasma concentration for a relatively long period of time is disclosed.

Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.

A stable solid controlled release formulation having a coating derived from an aqueous dispersion of a hydrophobic acrylic polymer includes a substrate including an active agent selected from the group consisting of a systemically active therapeutic agent, a locally active therapeutic agent, a disinfecting and sanitizing agent, a cleansing agent, a fragrance agent and a fertilizing agent, overcoated with an aqueous dispersion of the plasticized water-insoluble acrylic polymer. The formulation provides a stable dissolution of the active agent which is unchanged after exposure to accelerated storage conditions.

The present invention provides a lithium ion battery that exhibits a significantly improved specific capacity and much longer charge-discharge cycle life. In one preferred embodiment, the battery comprises an anode active material that has been prelithiated and pre-pulverized. This anode may be prepared with a method that comprises (a) providing an anode active material (preferably in the form of fine powder or thin film); (b) intercalating or absorbing a desired amount of lithium into the anode active material to produce a prelithiated anode active material; (c) comminuting the prelithiated anode active material into fine particles with an average size less than 10 μm (preferably <1 μm and most preferably <200 nm); and (d) combining multiple fine particles of the prelithiated anode active material with a conductive additive and/or a binder material to form the anode. Preferably, the prelithiated particles are protected by a lithium ion-conducting matrix or coating material. Further preferably, the matrix material is reinforced with nano graphene platelets.

Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.

Compositions are provided comprising a lipophilic active compound, e.g., a human or veterinary drug or a nutraceutical, interwoven with a polymeric matrix formed by two or more polymers, wherein one of the polymers is an amphiphilic polymer and the other polymer is either an amphiphilic polymer with a different hydrophobic-hydrophilic balance or a hydrophilic polymer, and the active lipophilic compound has modified physicochemical properties. The composition forms colloidal nanodispersion upon contact with aqueous media.

This invention provides a hybrid nano-filament composition for use as an electrochemical cell electrode. The composition comprises: (a) an aggregate of nanometer-scaled, electrically conductive filaments that are substantially interconnected, intersected, or percolated to form a porous, electrically conductive filament network comprising substantially interconnected pores, wherein the filaments have an elongate dimension and a first transverse dimension with the first transverse dimension being less than 500 nm (preferably less than 100 nm) and an aspect ratio of the elongate dimension to the first transverse dimension greater than 10; and (b) micron- or nanometer-scaled coating that is deposited on a surface of the filaments, wherein the coating comprises an anode active material capable of absorbing and desorbing lithium ions and the coating has a thickness less than 20 μm (preferably less than 1 μm). Also provided is a lithium ion battery comprising such an electrode as an anode. The battery exhibits an exceptionally high specific capacity, an excellent reversible capacity, and a long cycle life.

A device for forming a dental prosthesis includes a support and an element which can be attached thereto, such as an impression element. The support has an anchoring part for anchoring in a bone or a master model, a shoulder with an annular shoulder surface, and a head. The impression element has an elastically deformable fixing agent. When the device is assembled, the fixing agent jams and/or latches with the support, either externally on the support, on the side of the shoulder facing the anchoring part, or in an axial hole of the support. The element can be quickly detachably connected to the support by placing it on top of the support, and can be quickly separated from the support by moving the support away. When the device is assembled, the support and the element can lay on top of each other with annular surfaces. The annular surfaces have fully circular outer edges which are visible from the outside in an approximately radial viewing direction.

This invention provides a process for producing a hybrid nano-filament composition for use in a lithium battery electrode. The process comprises: (a) providing a porous aggregate of electrically conductive nano-wires that are substantially interconnected, intersected, physically contacted, or chemically bonded to form a porous network of electrically conductive filaments, wherein the nano-wires have a diameter or thickness less than 500 nm; and (b) depositing an electro-active coating onto a surface of the nano-wires, wherein the electro-active coating is capable of absorbing and desorbing lithium ions and the coating has a thickness less than 10 μm, preferably less than 1 μm. This process is applicable to the production of both an anode and a cathode. The battery featuring an anode or cathode made with this process exhibits an exceptionally high specific capacity, an excellent reversible capacity, and a long cycle life.

There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredients, rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates rapidly with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing one or more actives) with a taste-masking membrane applied by a modified solvent coacervation process comprising a water-insoluble polymer and at least one gastrosoluble inorganic or organic pore-former, exhibit a pleasant taste when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach.

There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity in about 60 seconds forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active) applied with a taste-masking membrane comprising a combination of water-insoluble and gastrosoluble polymers release not less than about 60% of the dose is in the stomach in about 30 minutes, thus maximizing the probability of achieving bioequivalence to the reference IR product having rapid onset of action (short T_max). A process for preparing such compositions for oral administration using conventional fluid-bed equipment and rotary tablet press is also disclosed.

PCT No. PCT/DK97/00101 Sec. 371 Date Jun. 22, 1998 Sec. 102(e) Date Jun. 22, 1998 PCT Filed Mar. 7, 1997 PCT Pub. No. WO97/32573 PCT Pub. Date Sep. 12, 1997An oral pharmaceutical modified release multiple-units composition for the administration of an analgesically effective amount of an opoid. The composition comprises at least two fractions wherein individual units containing an opoid are coated with a sustained release coating. A first fraction is adapted to relatively fast release while a second fraction is adapted to a delayed release. Such compositions make possible to obtain both a relatively fast onset of the analgesic effect and the maintenance of analgesically active plasma concentration for a relatively long period of time. The invention further relates to a process for the preparation of a composition according to the invention.

A formulation for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a non-toxic augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent. In preferred embodiments, the controlled release material is a low molecular weight, acid-terminated polymer. A further aspect of the invention is directed to such formulations which release the local anesthetic in two phases, the first a rapid "bolus" to initiate anesthesia and a second, slower release to maintain anesthesia.

Disclosed is a method of producing a hybrid nano-filament composition for use in a lithium battery electrode. The method comprises: (a) providing an aggregate of nanometer-scaled, electrically conductive filaments that are substantially interconnected, intersected, physically contacted, or chemically bonded to form a porous network of electrically conductive filaments, wherein the filaments comprise electro-spun nano-fibers that have a diameter less than 500 nm (preferably less than 100 nm); and (b) depositing micron- or nanometer-scaled coating onto a surface of the electro-spun nano-fibers, wherein the coating comprises an electro-active material capable of absorbing and desorbing lithium ions and the coating has a thickness less than 10 μm (preferably less than 1 μm). The same method can be followed to produce an anode or a cathode. The battery featuring an anode or cathode made with this method exhibits an exceptionally high specific capacity, an excellent reversible capacity, and a long cycle life.

The technology in this application provides a method and apparatus for efficiently using common uplink radio resources, e.g. a common uplink enhanced-dedicated physical channel (E-DCH) resource. A UE releases a common E-DCH resource very quickly after a completed transmission. In addition or alternatively, a base station may release a common E-DCH resource configuration from the network side to free up common E-DCH resources for use by other UEs. A low overhead signaling scheme for quickly and effectively releasing of common E-DCH resources between a UE and a base station is also described. For example, existing signaling fields on protocol layer 2 (L2) or layer 1 (L1) may be used. In one preferred example embodiment, signaling fields already in use in a CELL_DCH service state are given a different meaning for UEs in a CELL_FACH service state so that common E-DCH resources are quickly and effectively released.

In one embodiment, a method for generating an adaptive air interface waveform includes generating a waveform that includes a variable carrier frequency and variable bandwidth signal. The variable bandwidth signal includes one or more subcarriers that are dynamically placeable over a range of frequencies, and each subcarrier is separately modulated according to a direct sequence (DS) spread spectrum (SS) technique. The waveform has an embedded pilot usable to optimize one or more spectrum efficiencies of the waveform. A modulation constellation, a code rate, and a code length of the generated waveform are adapted according to an available spectrum and one or more sub-carrier conditions.

An enrobed solid form comprising a film enrobing a compacted fill material having at least one active material, the solid form shows a weight loss that is less than 1% during a 30 minutes USP Friability Test, the fill material having a density of at least 0.5 g/ml based on the total solid volume of the solid form and a tensile strength less than 0.9 MPa, and the at least one active material within the solid form has an immediate release profile. The solid form is useful in effective delivery of high dose levels of active material.

Described are pharmaceutical compositions comprising at least one steroidal drug such as a progestin (e.g. drospirenone, progesterone, eplerenone, etonogestrel) and/or an estrogen (estradiol and esters thereof) in molecularly dispersed form. The composition comprises a steroidal drug, preferably drospirenone, which is present in the composition in a non-particulate form. Preferably, the drug is present in a dissolved state in the excipient. The molecularly dispersed drug will be released very fast as dissolution takes place instantly when the dosage unit has disintegrated. Also described are methods for preparing the pharmaceutical compositions and methods of using the compositions.

The present invention provides a simple and improved osmotic device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use. One or both of the passageways optionally increases in size during use of the osmotic device. The preformed passageway and/or the second passageway increase the release rate of the active agent, enable the release of large particles containing active agent, and/or enable the release of active agents that are substantially insoluble in the environment of use. By virtue of the in situ formation of the second aperture, the device is able to release a greater overall percentage of active agent than it would release in absence of the second aperture.

A mounting bracket for a scope of a gun is disclosed. The mounting bracket is used to mount night scopes or telescopic scopes onto the barrel of a gun rapidly. The bracket comprises a seat body having a securing jaw, an actuating jaw and a triggering block, and the actuating jaw is pivotally mounted at the seat body and, together with the securing jaw, correspondingly grips the barrel of the gun. Further, the triggering block is pivotally mounted at the seat body, and the triggering block correspondingly urges or releases the actuating jaw. The user can rapidly disassemble the mounting bracket and the barrel of the gun. The direction of action of the triggering block is perpendicularly intersected with the vibration direction of the barrel and therefore the mounting bracket will not be dislocated in the course of shooting.

There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active), coated with a taste-masking membrane comprising a water-insoluble polymer and one or more gastrosoluble inorganic or organic pore-formers (practically insoluble in water and saliva, but soluble in an acidic buffer), exhibit acceptable taste-masking when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach.